Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Apr 26, 2010
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
Patients : total 220 patients
* Extrahepatic bile duct cancer : 55 patients for administration of COX2 55 patients for control group
* Pancreas cancer : 55 patients for administration of COX2 55 patients for control group
Indication
* After operation of extrahepatic bile duct cancer or pancreas cancer
* Age : 19 - 70 years old
* The patients who agree to consent sheet.
Contraindication
* Impossible of administration due to severe postoperative morbidities (bleeding, bowel obstruction, pancreatic fistula, biliary fistula)
* Preexisting heart disease: Ischemic heart disease, Heart failur...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patients who underwent operation for extrahepatic bile duct cancer or pancreas cancer
- • Between 19 and 70 years old
- • Agreed to consent sheet
- Exclusion Criteria:
- • The patients cannot administration of drug due to severe postoperative morbidities.
- • Preexisting heart disease: Ischemic heart disease, Heart failure. Severe uncontrolled hypertension (systolic BP\>160)
- • Renal insufficiency: CCR \< 50 or serum creatinin \>3.0
- • Hepatic insufficiency: Liver cirrhosis or active hepatitis
- • Preexisting allergic reaction history for NSAIDs or Sulfonamide
- • Current drug intake: Warfarin. Lithium, Fluconazole, Aspirin, Celecoxib
- • Preexisting Asthma. Especially aspirin-sensitive asthma.
- • Contraindications to aspirin, clopidogrel or celecoxib
- • When patients refused
- • Patients has psychological problem
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seonnam City, Gyeon Gi Do, Korea, Republic Of
Patients applied
Trial Officials
Ho-Seong Han, Professor
Study Chair
General surgery department
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials